Outcome of COVID-19 in liver transplant recipients: A preliminary report from Northwestern Italy

Transpl Infect Dis. 2020;00:e13353. wileyonlinelibrary.com/journal/tid  

|

© 2020 Wiley Periodicals LLC

1 | INTRODUCTION

After the initial outbreak in Hubei province in China in December

2019, COVID-19, a zoonosis caused by SARS-CoV-2 virus,1 _has

rap-idly spread worldwide and was declared a Public Health Emergency of International Concern by World Health Organization on January 30, 2020.

Shortly after, the first confirmed case of a COVID-positive patient was reported in Italy on January 31, 2020. Although containment measures were timely implemented by Italian Government, the outbreak spreads rapidly across Northern Italy and hits our Health system with unforeseen intensity. As of May 9th, 28 368 cases (7039 per million people) have been reported

in Piedmont (our Region in Northwestern Italy), with 140 patients

still admitted to intensive care units (ICU).2 _{Similarly to what has}

happened elsewhere, entire hospitals have been converted from their usual activity to COVID hospitals. In the meanwhile, surgi-cal activity has been restricted to emergency and high-risk on-cological cases.

Transplantation activity has been primarily affected by a de-crease of available donors, likely due to the diversion of ICU

re-sources toward the care of COVID-19 patients.3 _{However, despite}

concerns regarding the risk of donor-transmitted infection, peri-op-erative infection, and staff safety, liver transplantation (LT) has been considered an emergent and life-saving procedure and it has not been deliberately interrupted or reduced.

Received: 10 May 2020 

|

S H O R T C O M M U N I C A T I O N

Outcome of COVID-19 in liver transplant recipients: A

preliminary report from Northwestern Italy

Damiano Patrono

_{| Francesco Lupo}

_{| Francesca Canta}

_{| Elena Mazza}

_|

Stefano Mirabella

_{| Silvia Corcione}

_{| Francesco Tandoi}

_|

Francesco Giuseppe De Rosa

_{| Renato Romagnoli}

1_{General Surgery 2U – Liver Transplant} Unit, University of Torino, A.O.U. Città della Salute e della Scienza, Torino, Italy

2_{Department of Medical Sciences, Infectious} Diseases, University of Torino, A.O.U. Città della Salute e della Scienza, Torino, Italy Correspondence

Renato Romagnoli, General Surgery 2U - Liver Transplant Unit, University of Turin, Corso Bramante 88-90, 10126 Turin, Italy. Email: renato.romagnoli@unito.it

Abstract

Covid-19 pandemic is deeply affecting transplant activity worldwide. It is unclear whether solid organ transplant recipients are at increased risk of developing severe complications and how they should be managed, also concerning immunosuppres-sion. This is a report about the course and management of SARS-CoV-2 infection in liver transplant recipients from a single center in Northwestern Italy in the pe-riod March-April 2020. Three patients who were treated at our institution are re-ported in detail, whereas summary data are provided for those managed at peripheral Hospitals. Presentation varied from asymptomatic to rapidly progressive respiratory failure due to bilateral interstitial pneumonia. Accordingly, treatment and changes to immunosuppression were adapted to the severity of the disease. Overall mor-tality was 20%, whereas Covid-related mormor-tality was 10%. Two cases of prolonged (>2 months) viral carriage were observed in two asymptomatic patients who con-tracted the infection in the early course after transplant. Besides depicting Covid-19 course and possible treatment scenarios in liver transplant patients, these cases are discussed in relation to the changes in our practice prompted by Covid-19 epidemic, with potential implications for other transplant programs.

K E Y W O R D S

There is still limited knowledge about the course of COVID-19 in liver transplant recipients, especially in the case of early post-LT

infection.4,5 _{Recent series from USA}6 _{and Spain}7 _{have suggested}

that recipients of solid organ transplant affected by COVID-19 may present higher mortality as compared to the general population. However, these series reported pooled data for recipients of differ-ent organs and lacked an in-depth presdiffer-entation of cases.

This is a preliminary single-center report about the course of COVID-19 in liver transplant recipients. Three patients who were admitted at our institution are reported in detail, whereas a more general description is provided for seven more patients who were managed elsewhere or as outpatients, in which we were involved more indirectly. These cases are discussed also in the light of the changes to our practice they prompted and of the implications for other transplant programs.

2 | CASE REPORTS

Patient 1 was a 69-year-old gentleman with no major comorbidities, who received LT for hepatocellular carcinoma (HCC) arising on HBV and alcohol-related cirrhosis with model for end-stage liver disease score of 18 on March 5th, 2020. After an initially regular post-LT course, he was incidentally diagnosed as SARS-CoV-2-positive with

a nasopharyngeal swab (NPS) on his 5th post-LT day (POD) after his bed neighbor, who was recovering from a liver resection for HCC, had tested positive the previous day. This last patient, who was the first patient being diagnosed COVID-19 in our unit and died of the disease 13 days later, also infected 8 staff members before being isolated, prompting a steep change in our practice (see Discussion). Negative SARS-CoV-2 RNA test in the donor ruled out donor-recip-ient transmission. At the moment of diagnosis, patdonor-recip-ient 1 presented mild symptoms (rare coughs, temperature 37.5°C, no oxygen re-quirement). A computed tomography (CT) obtained on POD 6 did not show evidence of pneumonia (Figure 1). He was transferred to a COVID unit on POD 9 where he was administered hydroxychlo-roquine (HCQ) 200 mg bid for 16 days (Figure 2). Mycophenolate mofetil (MMF) dosing was reduced from 750 mg td to 500 mg td, and target tacrolimus (Tac) trough level was set at 5-7 ng/mL. Blood tests (Figure 3) were significant for mild lymphopenia, with levels com-parable with those pre-LT. He had an otherwise asymptomatic and uneventful course and was discharged home in quarantine on POD 27. More than two months after infection, he is alive and symptom-free, but still waiting for confirmation of viral clearance, as he tested positive on the last NPS performed on day 42 after the first proof of infection.

Patient 2 was a 59-year-old gentleman who was admitted for Covid-19-related bilateral interstitial pneumonia (Figure 1)

F I G U R E 1   Radiology findings. Only

minimal alterations, not typical for COVID-19, were observed in patient 1, whereas patients 2 and 3 had findings compatible with bilateral interstitial pneumonia. Patient 3, left panel: initial X-ray showing no sign of pneumonia; right panel: X-ray upon re-admission, compatible with bilateral interstitial pneumonia

8 months after LT for HCC in the setting of HBV-related and al-coholic cirrhosis. His medical history was significant for obesity with a body mass index of 31. Before admission, he had normal he-patic function and his immunosuppression (IS) consisted in melt-dose Tac 1.5 mg od and Everolimus 1 mg + 0.75 mg. He presented on March 19th with a 9-day history of fever (max 39°C), diarrhea, and mild dyspnea. On admission, vital parameters were as follows: blood pressure (BP) 140/90 mmHg, heart rate (HR) 100 bpm,

re-spiratory rate (RR) 26 bpm, and oxygen saturation (SpO₂) 96% in

room air. He was admitted and started on HCQ 200 mg bid and

O₂ therapy by facial mask, but never required continuous positive

airway pressure (CPAP) or mechanical ventilation to achieve oxy-gen saturation within normal limits. IS regimen was not modified. His laboratory values were significant for lymphopenia (minimum

0.43 × 108_{/L) and transient elevation of fibrinogen, C-reactive}

protein (CRP), and lactate dehydrogenase (LDH) (maximum levels 894 mg/dL, 120 mg/L and 677 IU/L, respectively). He did not

de-velop severe complications, was progressively weaned from O2,

and discharged home in quarantine on April 1st, 2020. Virological clearance was confirmed by two consecutive negative NPS on April 10th and 15th.

Patient 3, a 56-year-old gentleman with a history of smoking and LT for HCV-related cirrhosis in December 2016, presented on March 8th, 2020, due to a weeklong history of fever, sore throat, dry cough, and odynophagia. Before admission, his liver function tests were normal and IS consisted in prolonged-release Tac 1 mg od and Eve 1.5 mg td. Vital signs on admission were T 38.2°C, BP

120/80 mm Hg, HR 60 bpm, RR 12, and SpO2 99% in room air.

Although his chest X-ray was normal (Figure 1) and blood tests were only mildly altered (WBC 7.83 109/L, Lymphocytes 1.89 109/L, CRP 5.6 mg/L, ALT 82 IU/L), Covid-19 diagnosis was confirmed by RT-PCR on nasopharyngeal swab. Given the mild presentation, patient was discharged home in quarantine after a 48-hour observation period, with no specific treatment except suspension of Tac. Nine days after, however, he was transferred back to our Institution from

another hospital, where he presented for persistence of symptoms and appearance of mild dyspnea and fatigue. On admission, he had

BP 115/70 mm Hg, T 37.3°C, and SpO₂ 96%. Chest X-ray

demon-strated findings compatible with bilateral interstitial pneumonia (Figure 1). He was admitted and started on HCQ 200 mg bid. His Eve dosing had to be adjusted due to elevated trough levels (maximum 20.4 ng/mL), possibly due to pharmacological interaction with HCQ

(Figure 4). During admission, he required O2 therapy by facial mask,

from which he was progressively weaned off. Results of blood tests are depicted in Figure 3. He recovered well and tested negative for SARS-Cov-2 RT-PCR on three consecutive days (April 6th, 7th, and 8th) and was discharged home on April 9th.

Summary data for the whole series are provided in Table 1, but some details are worth mentioning. First, all patients had good liver function at the moment of diagnosis.

Patient 4 was also a bed neighbor of our index patient, and he had been discharged from hospital before COVID-19 was made in this last. He tested positive for SARS-CoV-2 RNA on a NPS per-formed 2 months after his LT, without having been in contact with other known COVID-19 patients. Thus, it is likely that he contracted the infection in the early post-LT course, similarly to patient 1. As he was presenting no symptoms, no specific treatment has been admin-istered and no changes have been made to his immunosuppression.

Patient 8 contracted the infection during a hospital admission for head trauma and, despite developing bilateral pneumonia, recov-ered from the disease and died of unrelated causes during the same hospital admission.

Patient 10 was admitted for a rectus abdominis muscle abscess and accidentally found to be positive for SARS-CoV-2 RNA on a surveillance NPS. As she presented no respiratory symptoms or evi-dence of pneumonia, no specific treatment was administered and IS was left unchanged.

In general, IS was reduced according to disease presentation and completely withdrawn in the only patient who died due to COVID-19. Six patients were administered HCQ, 3 high-dose steroids, and 2

F I G U R E 2   Synoptic view of the course of the disease, including duration of hospital admission, symptoms, treatment, and time of viral

shedding

Patient 1 5 d

Hospital Fever, dry cough

Hydroxychloroquine

+ + + +

Patient 2 8 m

Hospital Mild dyspnea, diarrhea, fever 39°C

Hydroxychloroquine, O2

+ + - -

Patient 3 3 y 3 m

Hosp. Hospital

Fever 39°C, dry cough Dyspnea, fatigue

Hydroxychloroquine, O2

+ - -

Time after LT*

-8 -6 -4 -2 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70

antivirals (lopinavir/ritonavir and darunavir/ritonavir). Overall, mor-tality was 20% and COVID-related mormor-tality was 10%.

3 | DISCUSSION

Covid-19 is a new disease and several questions concerning its course and management are still open, all the more in the specific population of solid organ transplant recipients. According to recent

observation about the course of COVID-19 in Northern Italy9 _and

data gathered from past severe acute respiratory distress syndrome

(SARS) and middle-east respiratory syndrome (MERS) epidemics,8

immunocompromised patients do not seem to be at increased risk of developing severe complications. However, data from recent series have suggested that solid organs transplant recipients contracting

COVID-19 may suffer from increased mortality as compared to the general population. 6,7

Data about the course of COVID-19 in LT recipients are still

lim-ited, especially for patients in the early stage after LT. Qin et al 5

reported a case of a patient who presented with fever on POD 2 and tested positive for SARS-CoV-2 on POD 12, after a CT scan demon-strated bilateral ground glass opacifications in its lungs. Tacrolimus and steroid doses were diminished, and patient was administered oseltamivir and intra-venous immunoglobulins. Oxygen require-ment was limited to high-flow nasal cannulae, and he was discharged

home on POD 58. Lagana et al4 _{have reported a case of likely}

COVID-related acute hepatitis in a 5-month-old recipient of living donor LT for biliary atresia. Although long-term follow-up was not available, the patient was recovering after treatment with HCQ and reduction of IS. Notably, transient worsening of liver enzymes was

F I G U R E 3   Line plots depicting time

trend of laboratory values. First values represent last available values before COVID-19 diagnosis. Asterisks represent the moment of COVID-19 infection

observed after treatment with steroid pulses, which were adminis-tered for concomitant features of acute cellular rejection. In the se-ries by Pereira et al,6 _{3 patients presented COVID-19 < 1 month after}

transplant, with two of them presenting mild/moderate disease, but it is was not specified whether they were recipients of a LT or of another solid organ.

We report here 10 cases of SARS-CoV-2 infection in LT recipi-ents at different times after transplant. In our series, COVID-related mortality was 10%. Considering that 8/10 patients were <70 years of age, this figure is higher to what we would expect in an age-matched group in Italy,10 _{in keeping with other series.}6,7 _{However, this could}

be an overestimate due to undetected asymptomatic cases. As of today, several National and International studies are under way to assess outcome and risk factors for severe complications in trans-plant patients affected by COVID-19, which will likely provide more precise estimates.

Two patients in our series (patients 1 and 4) contracted the in-fection in the early days after LT, but both of them presented with an indolent form of the disease. In particular, no treatment or changes to IS were considered in patient 4, as in his case COVID-19 went undetected during the likely 2 months of infection. This suggests that a higher IS load does not necessarily represent a risk factor for severe complications. However, increased IS could be associated to delayed viral clearance, as both patients exhibited prolonged viral shedding (>2 months).

Concerning IS, there is currently no clear evidence supporting systematic reduction or withdrawal of IS in transplant patients

af-fected by COVID-19.9 _{So far, our approach has been modulating IS}

load according to the severity of disease and concomitant treat-ments, considering that rejection treatment could potentially be more detrimental than stable IS. Furthermore, as patients with a se-vere course of the disease present higher levels of inflammatory cy-tokines, IS could theoretically be beneficial by controlling pulmonary hyperinflammation and reducing cytokine storm due to interleukins

and chemokine overproduction. Thus, it remains unclear whether increased mortality in transplant patients is associated with IS or rather with reduced organ function and/or associated comorbidities.

Our experience as a transplant unit also sheds some light into an otherwise gloomy scenario. Our Institution, a public university hos-pital hub for complex diseases in our Region, has managed sparing part of its resources for urgent operations and transplants. Our ex-perience with patient 1 prompted a deep reorganization of our activ-ity. Donors and recipients, as well as surgical patients in general, are systematically tested for SARS-CoV-2 using RT-PCR on NPS or bron-choalveolar lavage samples. After transplant, patients are admitted into a COVID-free ICU and afterward into a dedicated ward. Family visits have been suspended, and relatives are given news about pa-tients’ course on the phone. Other protected facilities, including a radiology department and an outpatient clinic, have also been im-plemented. Follow-up is done by telemedicine for patients not re-quiring physically attending clinic. While our transplant program is still active, we have not observed other hospital-acquired COVID-19 cases. In our opinion, notwithstanding that all efforts are mandatory to avoid infection of transplant patients,11 _{risks associated with the}

current pandemic should be weighed against that of candidate death or drop-out from the list. Obviously, any reasoning has to be contex-tualized to local logistics and resources.12,13

In conclusion, age-matched mortality seems higher in LT recipi-ents affected by COVID-19 as compared to the general population. Future studies are necessary to determine the role of organ function, associated comorbidities, and IS. Finally, our experience suggests that maintenance of transplant activity in the midst of COVID-19 pandemic is possible, provided protected pathways are ensured.

AUTHOR CONTRIBUTIONS

DP involved in study design, data collection and analysis, and man-uscript drafting; FL and FC involved in patient management and manuscript revision; EM performed data collection and manuscript

F I G U R E 4   Line plots depicting trough levels of tacrolimus and everolimus. First values represent last available values before COVID-19

T A B LE 1  Sy no pt ic t ab le o f p at ie nt c ou rs e a nd t re at m en t Sex A ge Ti m e po st -L T Lo ca tio n o f ma na gem en t Sy m pt om s In te rs titi al pne umo ni a Tr ea tm en t B as el in e I S C ha ng es t o I S O ut co me Pa tien t 1 a  M 69 5 d W ar d Fe ve r, dr y c ough No H CQ Ta c + M M F + Pr ed ↓ MMF A live Pa tien t 2 a  M 59 8 m o W ar d M ild d ys pn ea , di ar rhe a Ye s H C Q , O 2 Ta c + Ev e N one A live Pa tien t 3 a   M 56 3 y3 m o W ar d So re t hr oa t, d ry co ugh , f ev er Ye s H C Q , O 2 Ta c + Ev e St op Ta c A live Pa tien t 4 M 58 2 m o Ho me N one No N one Ta c + M M F + Pr ed N one A live Pa tien t 5 F 64 4a 4 m o W ar d Fe ve r, l ac k o f ap pe tit e, d ia rr he a Ye s St er oi ds , O 2 Ta c + Pr ed ↑P re d A live Pa tien t 6 M 64 8a W ar d Fe ve r Ye s H C Q , O 2, C PA P Ta c + M M F St op M M F, ↓ Ta c A live Pa tien t 7 M 64 9 y3 m o W ar d Fe ve r Ye s LP V/ RT V, H C Q , O 2 Ta c + M M F St op Ta c A live Pa tien t 8 M 62 11 a W ar d Fe ve r Ye s D RV /R TV , H C Q , st er oi ds , O 2 Ta c + M M F St op Ta c D ead b  Pa tien t 9 M 75 11 a8 m o W ar d D ia rrh ea, m ya lg ia, fe ve r, c ough Ye s St er oi ds , O 2 , C PA P Ta c + M PA St op M PA St op T ac D ead Pa tien t 1 0 F 85 22 a7 m o W ar d c  N one No N one Ta c N one A live A bb re vi at io ns : C PA P, c on tin uo us p os iti ve a ir w ay p re ss ur e; D RV /R TV , d ar una vir /r ito na vir ; E ve , e ve ro lim us ; H C Q , h yd ro xy ch ol or oq uin e; IS , im m un os up pr ess io n; L PV /R TV , l opi na vir /r ito na vir ; L T, li ve r tr an spl an ta tio n; M M F, m yc op heno la te m of et il; M PA , m yc op heno lic ac id ; P re d, p re dn is on e; T ac , t ac ro lim us . aCas es o f t he f irs t t hr ee p at ie nt s a re r ep or te d i n d et ai l i n t he m an us cr ip t. bD ec ea se d f or u nr el at ed c au se a ft er n eg at iv e C O V ID -1 9 t es t. cPa tie nt a dm itt ed f or r ec tu s a bd om in s a bs ce ss , a cc id en ta lly d ia gn os ed w ith S A RS -C oV -2 i nf ec tio n d ur in g a dm is si on .

revision; SM, SC, and FT revised the manuscript; FGD and RR revised the manuscript and supervised.

ORCID

Damiano Patrono https://orcid.org/0000-0002-4096-4504

REFERENCES

1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-269. 2. Dipartimento della Protezione Civile - COVID-19 Italia. http://

opend atadpc.maps.arcgis.com/apps/opsda shboa rd/index.html#/ b0c68 bce2c ce478 eaac8 2fe38 d4138b1. Accessed May 9th_{, 2020.}

3. Angelico R, Trapani S, Manzia TM, Lombardini L, Tisone G, Cardillo M. The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs. Am J Transplant. 2020. https://doi. org/10.1111/ajt.15904

4. Lagana SM, De Michele S, Lee MJ, et al. COVID-19 associated hepatitis complicating recent living donor liver transplanta-tion. Arch Pathol Lab Med. 2020. https://doi.org/10.5858/ arpa.2020-0186-SA

5. Qin J, Wang H, Qin X, et al. Perioperative presentation of COVID-19 disease in a liver transplant recipient. Hepatology. 2020. https:// doi.org/10.1002/hep.31257

6. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter. Am J

Transplant. 2020. https://doi.org/10.1111/ajt.15941

7. Fernandez-Ruiz M, Andres A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain.

Am J Transplant. 2020.https://doi.org/10.1111/ajt.15983

8. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18(8):e217-e227.

9. D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. 2020;26(6):832-834. 10. Mortality Risk of COVID-19. https://ourwo rldin data.org/morta

lity-risk-covid #case-fatal ity-rate-of-lity-risk-covid -19-by-age. Accessed May 9th_{, 2020.}

11. Michaels MG, La Hoz RM, Danziger-Isakov L, et al. Coronavirus dis-ease 2019: Implications of emerging infections for transplantation.

Am J Transplant. 2020. https://doi.org/10.1111/ajt.15832

12. Gori A, Dondossola D, Antonelli B, et al. Coronavirus disease 2019 and transplantation: a view from the inside. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15853

13. Maggi U, De Carlis L, Yiu D, et al. The impact of the COVID-19 out-break on liver transplantation programmes in Northern Italy. Am J

Transplant. 2020. https://doi.org/10.1111/ajt.15948

How to cite this article: Patrono D, Lupo F, Canta F, et al.

Outcome of COVID-19 in liver transplant recipients: A preliminary report from Northwestern Italy. Transpl Infect Dis.